Paradigm Biopharmaceuticals Ltd. (AU:PAR) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Paradigm Biopharmaceuticals Ltd. has received FDA approval to advance its Phase 3 clinical trial for knee osteoarthritis, marking a significant milestone for the company. With plans to begin patient enrollment in early 2025, Paradigm aims to enhance its strategic partnerships and commercial prospects. The trial will focus on assessing pain reduction and functional improvements, positioning Zilosul® as a promising treatment option.
For further insights into AU:PAR stock, check out TipRanks’ Stock Analysis page.
